Get the Stockscreener App
77.25
0.60%
0.805
Bright Minds Biosciences Inc stock is traded at $77.25, with a volume of 166.25K.
It is up +0.60% in the last 24 hours and up +1.02% over the past month.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
See More
Previous Close:
$76.44
Open:
$76.42
24h Volume:
166.25K
Relative Volume:
0.54
Market Cap:
$754.74M
Revenue:
-
Net Income/Loss:
$-19.80M
P/E Ratio:
-31.62
EPS:
-2.4426
Net Cash Flow:
$-14.56M
1W Performance:
-4.81%
1M Performance:
+1.02%
6M Performance:
-8.35%
1Y Performance:
+83.88%
1-Day Range:
$75.50
$78.65
1-Week Range:
$75.28
$81.50
52-Week Range:
$38.00
$123.75
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Name
Bright Minds Biosciences Inc
Sector
Industry
Phone
-
Address
-
Compare DRUG vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
76.92 | 750.03M | 0 | -19.80M | -14.56M | -2.4426 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.90 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.82 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.68 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.27 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Jefferies | Buy |
| Sep-08-25 | Initiated | BTIG Research | Buy |
| May-13-25 | Initiated | TD Cowen | Buy |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-23-25 | Initiated | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-25 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | Robert W. Baird | Outperform |
View All
Bright Minds Biosciences Inc Stock (DRUG) Latest News
BTIG Research Reiterates "Buy" Rating for Bright Minds Biosciences (NASDAQ:DRUG) - marketbeat.com
Liquidity Mapping Around (DRUG) Price Events - Stock Traders Daily
Bright Minds Biosciences (NASDAQ:DRUG) Issues Quarterly Earnings Results - marketbeat.com
Bright Minds (DRUG) reports Phase 2 seizure gains in treatment‑resistant epilepsy - Stock Titan
Bright Minds Biosciences (DRUG): Cormorant Asset Management reports 9.17% ownership stake - Stock Titan
Can Bright Minds (TSX:DRUG) Keep Biotech Momentum Going? - Kalkine Media
Adage Capital (DRUG) discloses 3.41% Bright Minds Biosciences stake in latest holding - Stock Titan
Bright Minds Biosciences Inc. expected to post a loss of C$1.76 a shareEarnings Preview - TradingView
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet - Yahoo Finance
Bright Minds Biosciences Inc (CN:DRUG) Shares Under Pressure as Biotech Sentiment Weakens and Development Risks Increase - kalkine.ca
Bright Minds: BMB-101 Takes Center Stage Ahead Of Phase 3 Pivotal Trials (NASDAQ:DRUG) - Seeking Alpha
Bright Minds Biosciences (CN:DRUG): The Ticker Everyone's Talking About After a US$175M Raise and a Seizure Data Bombshell - kalkine.ca
Bright Minds Biosciences Inc (CN:DRUG) Jumps 4.05%: neuroscience biotech's Canadian line rose to C$114 on almost no volume, a thin-trading blip rather than - kalkine.ca
Bright Minds Biosciences (DRUG) to Post Quarterly Earnings on Thursday - MarketBeat
Why (DRUG) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Perceptive Advisors LLC Sells 71,746 Shares of Bright Minds Biosciences Inc. $DRUG - MarketBeat
Janus Henderson Group PLC Raises Holdings in Bright Minds Biosciences Inc. $DRUG - marketbeat.com
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Rating of "Buy" from Brokerages - marketbeat.com
ADAR1 Capital Management LLC Has $2.47 Million Stock Position in Bright Minds Biosciences Inc. $DRUG - marketbeat.com
Bright Minds Biosciences Inc (DRUG) Cash Flow - TradingKey
40,000 Shares in Bright Minds Biosciences Inc. $DRUG Acquired by Orbimed Advisors LLC - MarketBeat
Bright Minds Biosciences Inc (DRUG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bright Minds Biosciences Inc (DRUG) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bright Minds Biosciences Inc (DRUG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bright Minds Biosciences Inc (DRUG) Institutional Confidence - TradingKey
DRUG|Bright Minds Biosciences Inc|Price:71.840|Chg%:+0.510 - TradingKey
Bright Minds Biosciences Inc (DRUG) Balance Sheet - TradingKey
Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High? - Yahoo Finance
Wall Street Analysts See a 27.16% Upside in Unity Software (U): Can the Stock Really Move This High? - Zacks Investment Research
Walleye Capital LLC Has $3.92 Million Holdings in Bright Minds Biosciences Inc. $DRUG - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Upgraded at Zacks Research - MarketBeat
All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy - Yahoo Finance
Brainsway (BWAY) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
Bright Minds Biosciences (DRUG) Rallies 4.25% as Shares Approach Key ResistanceSwing Entry Signals - dars.gov.et
Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 5%Should You Buy? - MarketBeat
Eli Lilly deal to buy AtaiBeckley (psychedelic) - KuCoin
Wall Street Analysts See a 27.35% Upside in Harmony Biosciences (HRMY): Can the Stock Really Move This High? - Yahoo Finance
Bright Minds Biosciences (DRUG) Climbs 2.55% as Bullish Momentum Builds Near Key ResistanceConversion Trade - dars.gov.et
Draig bags another $65M to speed testing of brain drugs - Yahoo Finance
Understanding Momentum Shifts in (DRUG) - Stock Traders Daily
Bright Minds Biosciences (DRUG) Faces Modest Pullback Amid Sector ConsolidationBPI Bear Confirmed - dars.gov.et
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 7.7%What's Next? - MarketBeat
Bright Minds Biosciences Inc Company Profile & Introduction - Moomoo
Epilepsy Pipeline Expands as 75+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart.com
Form 13D/A BRIGHT MINDS BIOSCIENCES INC. For: 2 July By Investing.com - Investing.com Canada
Ian McDonald reports 13.6% Bright Minds (DRUG) ownership stake - Stock Titan
Best TSX Healthcare Stocks to Watch for July 2026 - Kalkine Media
Avoiding Lag: Real-Time Signals in (DRUG) Movement - Stock Traders Daily
Canadian Securities Exchange Reports January 2026 Performance Figures - The Canadian Securities Exchange (CSE)
Bright Minds Biosciences (DRUG) Surges 3.51%, Testing Resistance at $75.19Equity Put Call - dars.gov.et
Indivior Pharmaceuticals Inc. (INDV) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
Bright Minds Biosciences Inc Stock (DRUG) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):